Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 37.61.
Forward PE Ratio (37.61) = Close Price ($72.32) / Consensus Forward EPS ($1.92)
FORWARD PE RATIO
37.61
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+88.85%
vs the sector median at left
Bio-Techne Corporation
Market Cap
$11.32B
Forward PE Ratio
37.61
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bio-Techne Corporation (TECH) | $11.32B | 37.61 |
| DaVita Inc. (DVA)vs › | $11.16B | 11.71 |
| Align Technology, Inc. (ALGN)vs › | $11.64B | 14.40 |
| Universal Health Services, Inc. (UHS)vs › | $10.73B | 7.85 |
| Molina Healthcare, Inc. (MOH)vs › | $10.46B | N/A |
| Insulet Corp. (PODD)vs › | $10.26B | 22.78 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.23B | 39.42 |
| Henry Schein, Inc. (HSIC)vs › | $10.08B | 16.44 |
| Tempus AI, Inc. (TEM)vs › | $12.74B | N/A |
| Exelixis, Inc. (EXEL)vs › | $13.59B | 18.14 |
Trailing P/E
62.3
reported TTM EPS
Forward P/E
37.6
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.92 implies +65.5% EPS growth vs the reported trailing $1.16.
At today's $72.32 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $2.06 | $1.95 – $2.17 | 3 | 35.2x |
| 2028-06-30 | $2.34 | $2.24 – $2.41 | 3 | 30.9x |
| 2029-06-30 | $2.68 | $2.58 – $2.83 | 1 | 27.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
